LIVIVO - Search results -

Search results

Result 1 - 10 of total 57

Search options

Article ; Online: Identification of Medication-Related Risks in Bariatric Surgery Patients by Performing Structured Medication Reviews.

Böhm, Doortje T M M / Berghuis, Kim / Said, Mohammed / Kerskes, Marieke C H M / Deenen, Maarten J / Bastiaans, Diane E T

Obesity surgery

2023 Volume 33, Issue 12, Page(s) 3932–3937

Abstract: Purpose: More medication-related issues are seen with the growing demand for bariatric surgery, because of possible altered pharmacokinetics after surgery. Collaboration with a pharmacist could improve the short- and long-term safety and efficacy of ... ...

Abstract	Purpose: More medication-related issues are seen with the growing demand for bariatric surgery, because of possible altered pharmacokinetics after surgery. Collaboration with a pharmacist could improve the short- and long-term safety and efficacy of pharmacotherapy in patients undergoing bariatric surgery. The aim of this study was to evaluate the impact of a structured medication review to identify medication-related risks before bariatric surgery. Materials and methods: The impact on pharmacy-led interventions of introducing a structured medication review was evaluated in a historically controlled study. In the retrospective part, we evaluated patient characteristics, medication use, and number of pre-surgery consultations with a pharmacist before the introduction of medication reviews. A flowchart was developed to detect the use of medicines with risks associated with bariatric surgery. In the prospective part, we evaluated pharmacy-led interventions after the introduction of structured medication reviews using the flowchart. Outcome effectiveness was measured through the number of pre-surgery pharmacy-led interventions. Results: Before using the flowchart for screening on risk medicines, 40 (2.6%) pharmacy-led interventions were identified in 1536 patients. In the prospective group, 195 patients were included and 88 (45%) interventions were identified (p < 0.001). Conclusion: A structured medication review before bariatric surgery significantly increased the number of pharmacy-led interventions in bariatric surgery patients. This procedure will shift interventions to pre-surgery instead of post-surgery, contributing to the optimization of pharmacotherapy at an early stage.
MeSH term(s)	Humans ; Medication Review ; Retrospective Studies ; Obesity, Morbid/surgery ; Bariatric Surgery ; Pharmaceutical Services
Language	English
Publishing date	2023-10-26
Publishing country	United States
Document type	Journal Article
ZDB-ID	1070827-3
ISSN	1708-0428 ; 0960-8923
ISSN (online)	1708-0428
ISSN	0960-8923
DOI	10.1007/s11695-023-06889-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3381: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: UGT1A1

Peeters, Sofía Lj / Deenen, Maarten J / Thijs, Anna Mj / Hulshof, Emma C / Mathijssen, Ron Hj / Gelderblom, Hans / Guchelaar, Henk-Jan / Swen, Jesse J

Pharmacogenomics

2023 Volume 24, Issue 8, Page(s) 435–439

Abstract: Tweetable abstract ... ...

Abstract	Tweetable abstract Pretreatment
MeSH term(s)	Humans ; Irinotecan/adverse effects ; Camptothecin/adverse effects ; Patient Safety ; Genotype ; Neoplasms/drug therapy ; Glucuronosyltransferase/genetics
Chemical Substances	Irinotecan (7673326042) ; Camptothecin (XT3Z54Z28A) ; Glucuronosyltransferase (EC 2.4.1.17)
Language	English
Publishing date	2023-07-20
Publishing country	England
Document type	Editorial
ZDB-ID	2019513-8
ISSN	1744-8042 ; 1462-2416
ISSN (online)	1744-8042
ISSN	1462-2416
DOI	10.2217/pgs-2023-0096
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5247: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Nomogram to Predict Severe Toxicity in DPYD Wild-Type Patients Treated With Capecitabine-Based Anticancer Regimens.

Knikman, Jonathan E / Lopez-Yurda, Marta / Meulendijks, Didier / Deenen, Maarten J / Schellens, Jan H M / Beijnen, Jos / Cats, Annemieke / Guchelaar, Henk-Jan

Clinical pharmacology and therapeutics

2023 Volume 115, Issue 2, Page(s) 269–277

Abstract: DPYD-guided dosing has improved the safety of fluoropyrimidine-based chemotherapy in recent years. However, severe toxicity remains in ~ 23% of patients not carrying DPYD variant alleles treated with capecitabine. Therefore, we developed a predictive ... ...

Abstract	DPYD-guided dosing has improved the safety of fluoropyrimidine-based chemotherapy in recent years. However, severe toxicity remains in ~ 23% of patients not carrying DPYD variant alleles treated with capecitabine. Therefore, we developed a predictive model based on patient-related and treatment-related factors aimed at estimating the risk of developing severe capecitabine-related toxicity. The nomogram was developed using data from two large clinical trials (NCT00838370 and NCT02324452). Patients with cancer carrying a DPYD variant allele (DPYD*2A, c.1236G>A, c.2846A>T, and c.1679T>G) were excluded. Univariable and multivariable logistic regression using predetermined predictors based on previous findings, including age, sex, body surface area, type of treatment regimen, and creatinine levels were used to develop the nomogram. The developed model was internally validated using bootstrap resampling and cross-validation. This model was not externally or clinically validated. A total of 2,147 DPYD wild-type patients with cancer treated with capecitabine-based chemotherapy regimens were included of which complete data of 1,745 patients were available and used for the development of the nomogram. Univariable and multivariable logistic regression showed that age, sex, and type of treatment regimen were strong predictors of severe capecitabine-related toxicity in DPYD wild-type patients. Internal validation demonstrated a concordance index of 0.68 which indicates a good discriminative ability for prediction of severe capecitabine-related toxicity. The developed nomogram includes readily available parameters and may be a helpful tool for clinicians to assess the risk of developing severe capecitabine-related toxicity in patients without known risk DPYD variant alleles treated with capecitabine-based anticancer regimens.
MeSH term(s)	Humans ; Capecitabine/adverse effects ; Fluorouracil/adverse effects ; Antimetabolites, Antineoplastic/adverse effects ; Nomograms ; Dihydrouracil Dehydrogenase (NADP)/genetics ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/chemically induced ; Genotype
Chemical Substances	Capecitabine (6804DJ8Z9U) ; Fluorouracil (U3P01618RT) ; Antimetabolites, Antineoplastic ; Dihydrouracil Dehydrogenase (NADP) (EC 1.3.1.2)
Language	English
Publishing date	2023-11-29
Publishing country	United States
Document type	Journal Article
ZDB-ID	123793-7
ISSN	1532-6535 ; 0009-9236
ISSN (online)	1532-6535
ISSN	0009-9236
DOI	10.1002/cpt.3100
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 20: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Is vancomycin clearance really correlated with hemoglobin? Arguments that it's not.

Deenen, Maarten J / Ter Heine, Rob

European journal of clinical pharmacology

2019 Volume 75, Issue 11, Page(s) 1617–1618

MeSH term(s)	Hemoglobins ; Humans ; Kinetics ; Sepsis ; Vancomycin
Chemical Substances	Hemoglobins ; Vancomycin (6Q205EH1VU)
Language	English
Publishing date	2019-07-27
Publishing country	Germany
Document type	Letter ; Comment
ZDB-ID	121960-1
ISSN	1432-1041 ; 0031-6970
ISSN (online)	1432-1041
ISSN	0031-6970
DOI	10.1007/s00228-019-02724-y
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 672: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.

Hulshof, Emma C / Deenen, Maarten J / Guchelaar, Henk-Jan / Gelderblom, Hans

European journal of cancer (Oxford, England : 1990)

2020 Volume 141, Page(s) 9–20

Abstract: Background: Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in most hospitals in patients starting irinotecan chemotherapy. The aim of this position paper was to evaluate the available evidence and to assess the potential value of ... ...

Abstract	Background: Pre-therapeutic UGT1A1 genotyping is not yet routinely performed in most hospitals in patients starting irinotecan chemotherapy. The aim of this position paper was to evaluate the available evidence and to assess the potential value of genotyping of UGT1A1∗28 and UGT1A16 in patients before starting treatment with irinotecan to reduce the risk of severe toxicity. Methods:* The literature was selected and assessed based on five pre-specified criteria: 1) the level of evidence for associations between UGT1A1 polymorphisms and irinotecan-induced severe toxicity, 2) clinical validity and utility of pre-therapeutic genotyping of UGT1A1, 3) safety and tolerability of irinotecan in carriers of UGT1A1 polymorphisms, 4) availability of specific dose recommendations for irinotecan in carriers of UGT1A1 polymorphisms, 5) evidence of cost benefits of pre-therapeutic genotyping of UGT1A1. Results: On all five criteria, study results were favourable for pre-therapeutic genotyping of UGT1A1. A high level of evidence (level I) was found for a higher incidence of irinotecan-induced severe toxicity in homozygous carriers of UGT1A128 or UGT1A16. The clinical validity and utility of this genetic test proved to be acceptable. Dose-finding studies showed a lower maximum tolerated dose in homozygous variant allele carriers, and most of the drug labels and guidelines recommend a dose reduction of 25-30% in these patients. In addition, pre-therapeutic genotyping of UGT1A1 is likely to save costs. Conclusion: Pre-therapeutic genotyping of UGT1A1 in patients initiating treatment with irinotecan improves patient safety, is likely to be cost-saving, and should, therefore, become standard of care.
MeSH term(s)	Antineoplastic Agents/adverse effects ; Drug-Related Side Effects and Adverse Reactions/genetics ; Genotype ; Glucuronosyltransferase/genetics ; Humans ; Irinotecan/adverse effects ; Pharmacogenomic Testing ; Polymorphism, Single Nucleotide
Chemical Substances	Antineoplastic Agents ; Irinotecan (7673326042) ; UGT1A1 enzyme (EC 2.4.1.-) ; Glucuronosyltransferase (EC 2.4.1.17)
Language	English
Publishing date	2020-10-23
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2020.09.007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: RE: Phase I dose escalation study of oxaliplatin delivered via a laparoscopic approach using pressurized intraperitoneal aerosol chemotherapy (PIPAC) for advanced peritoneal metastases of gastrointestinal tract cancers: PIPAC-oxaliplatin for peritoneal metastases of gastrointestinal cancers.

Rovers, Koen P / Lurvink, Robin J / Deenen, Maarten J / de Hingh, Ignace H J T

European journal of cancer (Oxford, England : 1990)

2021 Volume 147, Page(s) 182–184

MeSH term(s)	Aerosols ; Gastrointestinal Neoplasms ; Humans ; Laparoscopy ; Oxaliplatin ; Peritoneal Neoplasms/drug therapy
Chemical Substances	Aerosols ; Oxaliplatin (04ZR38536J)
Language	English
Publishing date	2021-02-24
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2021.01.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency.

Schouten, Jeroen F / Willems, Jeroen / Sanders, Stefan J W J / Creemers, Geert-Jan / Deenen, Maarten J

Clinical colorectal cancer

2021 Volume 20, Issue 4, Page(s) 359–363

MeSH term(s)	Colonic Neoplasms ; Dihydropyrimidine Dehydrogenase Deficiency ; Humans ; Pyrrolidines ; Rectal Neoplasms ; Thymine ; Trifluridine/adverse effects
Chemical Substances	Pyrrolidines ; tipiracil (NGO10K751P) ; Thymine (QR26YLT7LT) ; Trifluridine (RMW9V5RW38)
Language	English
Publishing date	2021-09-15
Publishing country	United States
Document type	Case Reports ; Journal Article
ZDB-ID	2112638-0
ISSN	1938-0674 ; 1533-0028
ISSN (online)	1938-0674
ISSN	1533-0028
DOI	10.1016/j.clcc.2021.09.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5798: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 435: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Response to letter entitled re: UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients: Is it time for everyone treated with irinotecan to be tested for UGT1A1 gene polymorphism?

Hulshof, Emma C / de With, Mirjam / Creemers, Geert-Jan / Guchelaar, Henk-Jan / Mathijssen, Ron Hj / Gelderblom, Hans / Deenen, Maarten J

European journal of cancer (Oxford, England : 1990)

2022 Volume 172, Page(s) 231–233

MeSH term(s)	Costs and Cost Analysis ; Genotype ; Glucuronosyltransferase/genetics ; Humans ; Irinotecan ; Polymorphism, Genetic ; Prospective Studies
Chemical Substances	Irinotecan (7673326042) ; Glucuronosyltransferase (EC 2.4.1.17)
Language	English
Publishing date	2022-07-03
Publishing country	England
Document type	Letter ; Comment
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2022.05.045
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The Effect of Genotyping on the Number of Pharmacotherapeutic Gene-Drug Interventions in Chronic Kidney Disease Patients.

Kerskes, Catharina H M / van den Eijnde, Carien J M E / Aarnoudse, Albert-Jan L H J / Grouls, René J E / Deiman, Birgit A L M / Deenen, Maarten J

Pharmacy (Basel, Switzerland)

2023 Volume 11, Issue 2

Abstract: Patients with chronic kidney disease (CKD) stage 3-5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 ( ...

Abstract	Patients with chronic kidney disease (CKD) stage 3-5 are polypharmacy patients. Many of these drugs are metabolized by cytochrome P450 (
Language	English
Publishing date	2023-04-04
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2737194-3
ISSN	2226-4787 ; 2226-4787
ISSN (online)	2226-4787
ISSN	2226-4787
DOI	10.3390/pharmacy11020069
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: Genetic Variants in DNA Repair Pathways as Potential Biomarkers in Predicting Treatment Outcome of Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: A Systematic Review.

Hulshof, Emma C / Lim, Lifani / de Hingh, Ignace H J T / Gelderblom, Hans / Guchelaar, Henk-Jan / Deenen, Maarten J

Frontiers in pharmacology

2020 Volume 11, Page(s) 577968

Abstract: Background: The introduction of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with either oxaliplatin or mitomycin C for patients with colorectal peritoneal metastasis (CPM) has resulted in a major increase in ...

Abstract	Background: The introduction of cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) with either oxaliplatin or mitomycin C for patients with colorectal peritoneal metastasis (CPM) has resulted in a major increase in overall survival. Nonetheless, despite critical patient selection, the majority of patients will develop recurrent disease within one year following CRS + HIPEC. Therefore, improvement of patient and treatment selection is needed and may be achieved by the incorporation of genetic biomarkers. This systematic review aims to provide an overview of genetic biomarkers in the DNA repair pathway that are potentially predictive for treatment outcome of patients with colorectal peritoneal metastases treated with CRS + HIPEC with oxaliplatin or mitomycin C. Methods: A systematic review was conducted according to the PRISMA guidelines. Given the limited number of genetic association studies of intraperitoneal mitomycin C and oxaliplatin in patients with CPM, we expanded the review and extrapolated the data from biomarker studies conducted in colorectal cancer patients treated with systemic mitomycin C- and oxaliplatin-based chemotherapy. Results: In total, 43 papers were included in this review. No study reported potential pharmacogenomic biomarkers in patients with colorectal cancer undergoing mitomycin C-based chemotherapy. For oxaliplatin-based chemotherapy, a total of 26 genetic biomarkers within 14 genes were identified that were signiﬁcantly associated with treatment outcome. The most promising genetic biomarkers were Conclusion: Several genetic biomarkers have proven predictive value for the treatment outcome of systemically administered oxaliplatin. By extrapolation, these genetic biomarkers may also be predictive for the efficacy of intraperitoneal oxaliplatin. This should be the subject of further investigation.
Language	English
Publishing date	2020-10-06
Publishing country	Switzerland
Document type	Systematic Review
ZDB-ID	2587355-6
ISSN	1663-9812
ISSN	1663-9812
DOI	10.3389/fphar.2020.577968
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito